Olema Pharmaceuticals $240 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $240 million initial public offering of 12,650,000 shares of common stock of Olema Oncology at $19…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Antengene HK$2.79 billion IPO
Davis Polk advised Antengene Corporation Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule…
Auna $300 million high-yield notes offering
Davis Polk advised Auna S.A.A. in connection with its Rule 144A/Regulation S offering of $300 million aggregate principal amount of its 6.500% senior notes due 2025. The notes are…
Kodiak Sciences $645 million follow-on offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $645.0 million public offering of 5,972,222 shares of common stock by…
Five Prime Therapeutics $173 million follow-on offering
Davis Polk advised the joint-bookrunning managers and representatives of the several underwriters in connection with an approximately $173.8 million public offering of common stock by…
Bristol Myers Squibb $7 billion notes offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with an SEC-registered public debt offering by Bristol-Myers Squibb Company,…
BioNTech $500 million SEC-registered at-the-market offering
Davis Polk advised the sales agents in connection with an SEC-registered at-the-market offering by BioNTech SE of its ordinary shares represented by American depositary shares for up to an…
Affimed $75 million SEC-registered at-the-market offering program
Davis Polk advised the sales agent in connection with the establishment of an SEC-registered at-the-market offering program by Affimed N.V. of up to $75 million gross sales price of…
RemeGen HK$4 billion Hong Kong IPO
Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A…
NovoCure $575 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited of $575 million aggregate principal amount of its 0.000%…